Renee Gaeta Sells 17,672 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CFO Renee Gaeta sold 17,672 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the transaction, the chief financial officer directly owned 113,753 shares in the company, valued at approximately $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Performance

NASDAQ:OM opened at $4.58 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97. Outset Medical, Inc. has a 1 year low of $3.00 and a 1 year high of $21.98. The stock’s 50 day simple moving average is $4.26 and its two-hundred day simple moving average is $4.17. The company has a market cap of $84.91 million, a price-to-earnings ratio of -1.10 and a beta of 1.95.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%.The firm had revenue of $27.86 million during the quarter, compared to the consensus estimate of $28.90 million. As a group, equities analysts anticipate that Outset Medical, Inc. will post -3.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Friday, March 27th. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, BTIG Research reduced their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Outset Medical presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Outset Medical

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its position in shares of Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after purchasing an additional 176,870 shares during the last quarter. Sei Investments Co. increased its position in shares of Outset Medical by 15.5% during the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock valued at $136,000 after purchasing an additional 4,738 shares during the last quarter. BML Capital Management LLC increased its position in shares of Outset Medical by 250.2% during the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after purchasing an additional 1,359,021 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Outset Medical by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after purchasing an additional 2,435 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Outset Medical during the 1st quarter valued at approximately $65,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.